These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 10852343)
1. Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients. Ward CM; Acheson N; Seymour LW J Drug Target; 2000; 8(2):119-23. PubMed ID: 10852343 [TBL] [Abstract][Full Text] [Related]
2. Folate-targeted non-viral DNA vectors for cancer gene therapy. Ward CM Curr Opin Mol Ther; 2000 Apr; 2(2):182-7. PubMed ID: 11249640 [TBL] [Abstract][Full Text] [Related]
3. Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate. Hwa Kim S; Hoon Jeong J; Joe CO; Gwan Park T J Control Release; 2005 Apr; 103(3):625-34. PubMed ID: 15820409 [TBL] [Abstract][Full Text] [Related]
4. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Zhang L; Hou S; Mao S; Wei D; Song X; Lu Y Int J Pharm; 2004 Dec; 287(1-2):155-62. PubMed ID: 15541922 [TBL] [Abstract][Full Text] [Related]
5. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Turk MJ; Waters DJ; Low PS Cancer Lett; 2004 Sep; 213(2):165-72. PubMed ID: 15327831 [TBL] [Abstract][Full Text] [Related]
6. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160 [TBL] [Abstract][Full Text] [Related]
7. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells. Gabor F; Wollmann K; Theyer G; Haberl I; Hamilton G Anticancer Res; 1994; 14(5A):1943-50. PubMed ID: 7847832 [TBL] [Abstract][Full Text] [Related]
8. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763 [TBL] [Abstract][Full Text] [Related]
9. Application of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes for gene transfer into human ovarian carcinoma cells. Verbaan FJ; Klein Klouwenberg P; van Steenis JH; Snel CJ; Boerman O; Hennink WE; Storm G Int J Pharm; 2005 Nov; 304(1-2):185-92. PubMed ID: 16129577 [TBL] [Abstract][Full Text] [Related]
10. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Kelly FJ; Miller CR; Buchsbaum DJ; Gomez-Navarro J; Barnes MN; Alvarez RD; Curiel DT Clin Cancer Res; 2000 Nov; 6(11):4323-33. PubMed ID: 11106250 [TBL] [Abstract][Full Text] [Related]
11. Fluorescein isothiocyanate labelled bovine serum albumin (FITC-BSA) as a model protein drug: opportunities and drawbacks. Wischke C; Borchert HH Pharmazie; 2006 Sep; 61(9):770-4. PubMed ID: 17020153 [TBL] [Abstract][Full Text] [Related]
12. Flow cytometric analysis of fluorescein-conjugated estradiol (E-BSA-FITC) binding in breast cancer suspensions. Benz C; Wiznitzer I; Lee SH Cytometry; 1985 May; 6(3):260-7. PubMed ID: 3996141 [TBL] [Abstract][Full Text] [Related]
13. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196 [TBL] [Abstract][Full Text] [Related]
14. Epithelial cancer cell migration: a role for chemokine receptors? Scotton CJ; Wilson JL; Milliken D; Stamp G; Balkwill FR Cancer Res; 2001 Jul; 61(13):4961-5. PubMed ID: 11431324 [TBL] [Abstract][Full Text] [Related]
15. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425 [TBL] [Abstract][Full Text] [Related]
16. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Provencher DM; Finstad CL; Saigo PE; Rubin SC; Hoskins WJ; Federici MG; Stockert E; Lloyd KO; Lewis JL Gynecol Oncol; 1993 Jul; 50(1):78-83. PubMed ID: 8349167 [TBL] [Abstract][Full Text] [Related]
17. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cannistra SA; Kansas GS; Niloff J; DeFranzo B; Kim Y; Ottensmeier C Cancer Res; 1993 Aug; 53(16):3830-8. PubMed ID: 8339295 [TBL] [Abstract][Full Text] [Related]
18. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Berry NB; Cho YM; Harrington MA; Williams SD; Foley J; Nephew KP Gynecol Oncol; 2004 Mar; 92(3):896-904. PubMed ID: 14984958 [TBL] [Abstract][Full Text] [Related]
19. Selective targeting of malignant cells with cytotoxin-folate conjugates. Leamon CP; Low PS J Drug Target; 1994; 2(2):101-12. PubMed ID: 8069588 [TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]